Browsing by Author "Bezawit Tesfaye"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Risk Factors Impacting Sustainable Construction Project Performance: The case of East Africa Specialized Engineering Plc (Ease) in Ethiopia
    (Addis Ababa University, 2024-10) Bezawit Tesfaye; Seifu Mamo (PhD)
    Ethiopia's construction industry is crucial for the nation's economy, with billions of Birr annually.Sustainable construction aims to minimize environmental impacts while delivering economic benefits. However, these projects face unique uncertainties due to the rapid development ofsustainable techniques and technologies. This study aims to identify and analyze risk factors influencing the performance of sustainable building projects. The study used primary andsecondary data, including questionnaires and interviews, and the construction industry's annual reports. The study population was selected using cencus inquiry. The study design is quantitativeand explanatory. 80 responses were gathered from 94 disseminated surveys. Descriptive and inferential data analysis methods were applied. The findings showed that all identified predictors(material and technology risks, stakeholder risks, technical risks, management risks, and regulatory and economic risks) have a significant relationship with project performance, with thefive independent factors having a combined 38.7% influence. It is advised that East Africa Specialized Engineering PLC (EASE) endeavor to reduce the likelihood of these risk variablesmaterializing to improve project performance. words: project performance, Sustainable Construction Project, Risk, Risk analysis, Riskidentification
  • No Thumbnail Available
    Item
    The Preparation And Efficacy Evaluation Of Combined Vaccine Against Peste Des Petits Ruminants And Sheepox And Goatpox
    (Addis Abeba University, 2025) Bezawit Tesfaye; Dr. Samson Leta; . Dr. Haileleul Negussie
    Peste des petits ruminants (PPR), sheeppox (SP) and goatpox (GP) are economically important diseases in Ethiopia. These diseases are commonly distributed throughout Ethiopia, hindering productivity and leading to substantial economic losses. Given Ethiopia's ambitious goal to eradicate PPR by 2027, this research aimed to develop and evaluate the efficacy of a combined vaccine by starting with the preparation of monovalent PPR and SP/GP live attenuated vaccines separately using Vero cell culture and with the determined titer 4.8 log10 TCID50 per ml and 4.6 log10 TCID50 per ml respectively, before being combined. Quality control tests, including sterility, moisture content, and safety in guinea pigs, were performed. A total of 10 sheep and goats were immunized, and their immune responses were monitored through daily body temperature readings that was maintained in the normal range between 37.38oC-39.32oC, C- ELISA test result for antibody detection of PPR read its peak on 10.59% for group A and 10.58% for group B, while Group C remained with no antibody, heightened that Group A and B animals confers protection up on natural infection. The SNT test results also revealed that vaccinated animals in each group had strong antibody titers against SP/GP, defined as values greater than 1.5 log10. Each of these animals challenged by PPR and GP viruses isolated on Verodog-SLAM for PPRV and on Vero and ESH-L cells for GPV. Finally, the challenge experiment discloses that vaccinated animals stayed in their normal behavior while control animals unequivocally manifested disease-specific clinical signs, which was confirmed by molecular detection of nucleic acids of both viruses. These findings underscore the vaccine's robust efficacy in preventing overt disease and secured immunogenicity of both vaccines. Further researches on the deployment of this live attenuated combined vaccine on a field basis have of utmost importance to completely asses its efficacy and effectiveness.